NCT06585527View on ClinicalTrials.gov

Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 29, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions

Glioblastoma MultiformeGlioma, Malignant

Interventions

BIOLOGICAL

TS-2021

The participants meeting the criteria will undergo TS-2021 oncolytic virus (5×1011PFU/ml) intratumoral injection using stereotactic technique under MR Localization.

Trial Locations (1)

100050

RECRUITING

Beijing Tiantan Hospital, Beijing

All Listed Sponsors

lead

Beijing Neurosurgical Institute

OTHER